Investor Presentaiton slide image

Investor Presentaiton

Highly experienced leadership team Clarity's management team has a diverse and in-depth level of expertise spanning corporate finance, management, operations, commercialisation and industry Dr Alan Taylor Executive Chairman Dr Colin Biggin Managing Director, Dr Matt Harris Chief Scientific Officer CEO Michelle Parker Director of Clinical Operations Dr Jennifer Rosenthal Director of Quality and Regulatory Affairs Shaemus Gleason Executive VP, US Operations David Green Chief Financial Officer Dr Taylor has been instrumental in the growth of the Company and has been heavily involved in all areas of the Company's business. Dr Taylor has approximately 15 years of investment banking experience focused predominantly on the life. sciences sector, and has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank. Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium- 223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals. Dr Harris has approximately 20 years of combined experience in cancer research, nuclear medicine and business and has a PhD in cancer research from the Australian National University. Dr Harris brings expertise in biotechnology. radiopharmaceuticals, academic research and investment to the Company and focuses on developing the technology behind the Company's products. Ms Parker has over 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution. Dr Rosenthal has over 20 years of management experience in the biotechnology industry, serving in senior director and executive level roles with an oncology focus. She has successfully developed strategy, and managed teams and projects in the areas of regulatory affairs (agencies include US FDA, EMA and Australian TGA), clinical trials, quality assurance and IP. Prior to joining Clarity, Dr Rosenthal managed the global regulatory team at the previously ASX-listed company Viralytics Limited, which was acquired by Merck & Co for $502 million in 2018. Prior to Viralytics, Jennifer spent 10 years at Alchemia Limited, and at Florigene and Davies Collison Cave Patent and Trademark Attorneys. Mr Gleason has over 13 years of experience spanning across all facets of targeted radionuclide therapies and diagnostic radiopharmaceuticals. Prior to joining the Company, he was a member of the oncology strategy business unit at Bayer/Algeta where he was responsible for the technical operations in their phase I targeted alpha therapy development globally. Prior to this, he held a leadership role on the US commercial organisation supporting a marketed product Xofigo® (radium- 223 dichloride) for metastatic prostate cancer. Mr Green has over 25 years' experience in performing senior finance roles for listed and unlisted companies, including Pacific Dunlop Limited, Sigma Pharmaceuticals, Alchemia Limited, Chiquita Brands South Pacific Limited (now Costa Group) and Ellume Limited. As a proven CFO, he has extensive experience in complex operating environments across multiple geographies, private treaty and public company transactions, treasury operations and debt and equity markets. CLARITY 2014 M 31
View entire presentation